申请人:John Wyeth & Brothers Limited
公开号:US04959375A1
公开(公告)日:1990-09-25
Piperidine derivatives of the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof wherein A represents an aromatic radical selected from ##STR2## wherein R.sup.3 is hydrogen, (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy or halogen; X.sup.1 -X.sup.2 represents CH.sub.2 --CH, NR.sup.4 --CH, O--CH, S--CH, CH.sub.2 --N, O--N, S--N, NR.sup.4 --N, CH--NR.sup.4 or N--NR.sup.4 [where R.sup.4 is hydrogen, (C.sub.1-4)alkyl, phenyl or phenyl(C.sub.1-4)alkyl] or ##STR3## wherein R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are independently hydrogen, halogen, trifluoromethyl, (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy, hydroxy, nitro, amino, (C.sub.1-4)alkylamino, di(C.sub.1-4)alkyl-amino, (C.sub.2-4)alkanoylamino, mercapto or (C.sub.1-4)alkylthio and R.sup.1 and R.sup.2 are independently hydrogen, (C.sub.1-4)alkyl or (C.sub.1-4)alkylphenyl or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached represent pyrrolidino or piperidino possess 5-HT.sub.3 -antagonistic activity.
该文献描述了公式为##STR1##的吡啶衍生物及其药学上可接受的酸盐,其中A代表从##STR2##中选择的芳香基团,其中R.sup.3为氢,(C.sub.1-4)烷基,(C.sub.1-4)烷氧基或卤素; X.sup.1 -X.sup.2代表CH.sub.2 --CH,NR.sup.4 --CH,O--CH,S--CH,CH.sub.2 --N,O--N,S--N,NR.sup.4 --N,CH--NR.sup.4或N--NR.sup.4 [其中R.sup.4为氢,(C.sub.1-4)烷基,苯基或苯基(C.sub.1-4)烷基]或##STR3##其中R.sup.5,R.sup.6,R.sup.7和R.sup.8分别为氢,卤素,三氟甲基,(C.sub.1-4)烷基,(C.sub.1-4)烷氧基,羟基,硝基,氨基,(C.sub.1-4)烷基氨基,二(C.sub.1-4)烷基-氨基,(C.sub.2-4)烷酰胺基,巯基或(C.sub.1-4)烷基硫基,而R.sup.1和R.sup.2分别为氢,(C.sub.1-4)烷基或(C.sub.1-4)烷基苯基,或R.sup.1和R.sup.2与它们连接的氮原子一起代表吡咯烷基或哌嗪基,具有5-HT.sub.3拮抗活性。